HRT Financial’s Metagenomi Therapeutics MGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$55K Buy
+52,288
New +$62.9K ﹤0.01% 4301
2026
Q2
– Sell
-10,674
Closed -$14K – 5535
2026
Q1
$14K Sell
10,674
-417
-4% -$648 ﹤0.01% 3609
2025
Q4
$17K Sell
11,091
-3,006
-21% -$6.51K ﹤0.01% 3003
2025
Q3
$33K Sell
14,097
-44,946
-76% -$91.2K ﹤0.01% 2649
2025
Q2
$87K Buy
+59,043
New +$92.5K ﹤0.01% 2227
2024
Q2
– Sell
-31,477
Closed -$332K – 3258
2024
Q1
$332K Buy
+31,477
New +$362K ﹤0.01% 1497

Other funds holding MGX

HRT Financial's MGX Position: Q3 2026 in Review

HRT Financial opened a new position in Metagenomi Therapeutics (MGX) in Q3 2026: 52,288 shares worth $55K. The stake represents ﹤0.01% of the portfolio and ranks #4301 among its holdings. This is a return to the name: HRT Financial previously reported a position in MGX as recently as Q1 2026.

HRT Financial first reported a position in MGX in Q1 2024 and has held it in 6 quarters since. The position peaked at $332K in Q1 2024. 44 funds tracked by Wall St. Rank hold MGX as of Q3 2026.

  • HRT Financial held 52,288 shares of Metagenomi Therapeutics worth $55K as of Q3 2026.
  • Metagenomi Therapeutics was a new HRT Financial position in Q3 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q3 2026, its #4301 holding.
  • HRT Financial first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • HRT Financial's Metagenomi Therapeutics position peaked at $332K in Q1 2024.
  • 44 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2026.

Based on HRT Financial's 13F filing for Q3 2026, filed 13 Nov 2026.